These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 14723107

  • 1. Dry eye moves beyond palliative therapy.
    Sheppard JD.
    Manag Care; 2003 Dec; 12(12 Suppl):6-8. PubMed ID: 14723107
    [Abstract] [Full Text] [Related]

  • 2. Dry eye: prevalence, utilization, and economic implications.
    Dalzell MD.
    Manag Care; 2003 Dec; 12(12 Suppl):9-13. PubMed ID: 14723108
    [Abstract] [Full Text] [Related]

  • 3. Inflammation: a unifying theory for the origin of dry eye syndrome.
    Wilson SE.
    Manag Care; 2003 Dec; 12(12 Suppl):14-9. PubMed ID: 14723109
    [Abstract] [Full Text] [Related]

  • 4. Antiinflammatory therapy for dry eye.
    Pflugfelder SC.
    Am J Ophthalmol; 2004 Feb; 137(2):337-42. PubMed ID: 14962426
    [Abstract] [Full Text] [Related]

  • 5. Considerations in the pharmacoeconomics of dry eye.
    Hirsch JD.
    Manag Care; 2003 Dec; 12(12 Suppl):33-8. PubMed ID: 14723112
    [Abstract] [Full Text] [Related]

  • 6. Medications for dry eye syndrome: a drug-therapy review.
    Perry HD, Donnenfeld ED.
    Manag Care; 2003 Dec; 12(12 Suppl):26-32. PubMed ID: 14723111
    [Abstract] [Full Text] [Related]

  • 7. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys.
    Trattler W, Katsev D, Kerney D.
    Clin Ther; 2006 Nov; 28(11):1848-56. PubMed ID: 17213005
    [Abstract] [Full Text] [Related]

  • 8. Guidelines for the treatment of chronic dry eye disease.
    Sheppard JD.
    Manag Care; 2003 Dec; 12(12 Suppl):20-5. PubMed ID: 14723110
    [Abstract] [Full Text] [Related]

  • 9. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M, Okada N, Igarashi A, Kujira A, Fujishima H, Okamoto S, Shimazaki J, Tsubota K.
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [Abstract] [Full Text] [Related]

  • 10. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
    Lee HK, Ryu IH, Seo KY, Hong S, Kim HC, Kim EK.
    Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
    [Abstract] [Full Text] [Related]

  • 11. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
    Cordero-Coma M, Anzaar F, Sobrin L, Foster CS.
    Ocul Immunol Inflamm; 2007 Feb; 15(2):99-104. PubMed ID: 17558834
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinically important difference in dry eye: change in IDEEL-symptom bother.
    Fairchild CJ, Chalmers RL, Begley CG.
    Optom Vis Sci; 2008 Aug; 85(8):699-707. PubMed ID: 18677226
    [Abstract] [Full Text] [Related]

  • 14. [Dry eye syndrome in rheumatoid arthritis patients].
    Polanská V, Hlinomazová Z, Fojtík Z, Nemec P.
    Cesk Slov Oftalmol; 2007 Nov; 63(6):422-30. PubMed ID: 18062166
    [Abstract] [Full Text] [Related]

  • 15. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca.
    Stonecipher K, Perry HD, Gross RH, Kerney DL.
    Curr Med Res Opin; 2005 Jul; 21(7):1057-63. PubMed ID: 16004673
    [Abstract] [Full Text] [Related]

  • 16. Responses to a dry eye questionnaire from a normal population.
    McMonnies CW, Ho A.
    J Am Optom Assoc; 1987 Jul; 58(7):588-91. PubMed ID: 3668156
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.